Introduction: Heart failure (HF) is a complex, progres-sive disease which affects the heart’s pumping function with direct effect on blood circulation through decre-asing cellular oxygenation and decreasing nutrients in whole body.
Objective: In this randomized study, we observed the correlation between coenzyme Q10 supplementation and quality of life improvement in patients with heart failure.
Methods: This study was conducted between 2018 and 2019 in Timisoara’s Preventive Cardiology and Cardio-vascular Rehabilitation Clinic on a group of 60 patients with heart failure. The patients were randomized in 2 groups: coenzyme Q10 supplementation (100mg/ day) CardioQ10 and placebo. The exclusion criteria for the study were: body mass index (BMI)> 40 kg/m2, chronic inflammatory diseases, hepatic and kidney diseases, cancer, frequent use of anti-inflammatory medication and patients who took antioxidants and micronutrients supplements in the previous 6 months. Patients were evaluated through physical examination, ECG, tran-sthoracic echocardiography, 6 minute walk test and Minnesota Living with Heart Failure questionnaire (MLHFQ).
Results: The lot included 35 men and 25 women, out of which 10 patients with heart failure NYHA II, 37 with NYHA III and 13 with NYHA IV. Mean age was 69 years. Mann-Whitney Test revealed a significantly im-provement in systolic blood pressure – SBP (p<0.031), diastolic blood pressure – DBP (p<0.024) and MLHFQ (p<0.001) for the CardioQ10 group at 3 months. Ejec-tion fraction (EF) was not significantly modified. Wil-coxon Signed Ranks Test showed a significantly im-provement for SBP (p<0.009), DBP (p<0.034), NYHA class (p<0.001), weight (p<0.001), BMI (p<0.001) and MLHFQ (p<0.001) in the CardioQ10 group at 3 months. EF wasn’t significantly decreased (p<0,33).
Conclusions: T his study demonstrated an improve-ment in SBP, DBP, weight, BMI, NYHA class and qua-lity of life (MLHFQ) in CardioQ10 group compared to the placebo group.
This work is licensed under a